ID   GIST882
AC   CVCL_7044
SY   GIST-882; GIST 882
DR   cancercelllines; CVCL_7044
DR   ChEMBL-Cells; CHEMBL4513108
DR   ChEMBL-Targets; CHEMBL4513126
DR   Cosmic; 1180672
DR   Cosmic; 1217560
DR   Cosmic; 1244759
DR   Cosmic; 1477623
DR   Cosmic; 1873949
DR   Cosmic; 2805389
DR   GEO; GSM486234
DR   GEO; GSM2527254
DR   GEO; GSM2527255
DR   GEO; GSM2786738
DR   Lonza; 694
DR   Progenetix; CVCL_7044
DR   PubChem_Cell_line; CVCL_7044
DR   Wikidata; Q54835862
RX   PubMed=11526490;
RX   PubMed=16077968;
RX   PubMed=16982758;
RX   PubMed=19706776;
RX   PubMed=25239608;
RX   PubMed=29866822;
RX   PubMed=30488756;
CC   Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Lys642Glu (c.1924A>G); ClinVar=VCV000013866; Zygosity=Homozygous (PubMed=11526490; PubMed=16077968).
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Cell type: Interstitial cell of Cajal; CL=CL_0002088.
DI   NCIt; C3868; Gastrointestinal stromal tumor
DI   ORDO; Orphanet_44890; Gastrointestinal stromal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 17
//
RX   PubMed=11526490; DOI=10.1038/sj.onc.1204704;
RA   Tuveson D.A., Willis N.A., Jacks T., Griffin J.D., Singer S.,
RA   Fletcher C.D.M., Fletcher J.A., Demetri G.D.;
RT   "STI571 inactivation of the gastrointestinal stromal tumor c-KIT
RT   oncoprotein: biological and clinical implications.";
RL   Oncogene 20:5054-5058(2001).
//
RX   PubMed=16077968; DOI=10.3892/or.14.3.645;
RA   Noma K., Naomoto Y., Gunduz M., Matsuoka J., Yamatsuji T.,
RA   Shirakawa Y., Nobuhisa T., Okawa T., Takaoka M., Tomono Y.,
RA   Hiroyuki O., Gunduz E., Tanaka N.;
RT   "Effects of imatinib vary with the types of KIT-mutation in
RT   gastrointestinal stromal tumor cell lines.";
RL   Oncol. Rep. 14:645-650(2005).
//
RX   PubMed=16982758; DOI=10.1158/0008-5472.CAN-06-0165;
RA   Bauer S., Yu L.K., Demetri G.D., Fletcher J.A.;
RT   "Heat shock protein 90 inhibition in imatinib-resistant
RT   gastrointestinal stromal tumor.";
RL   Cancer Res. 66:9153-9161(2006).
//
RX   PubMed=19706776; DOI=10.1158/0008-5472.CAN-08-4004;
RA   Muhlenberg T., Zhang Y.-X., Wagner A.J., Grabellus F., Bradner J.,
RA   Taeger G., Lang H., Taguchi T., Schuler M., Fletcher J.A., Bauer S.;
RT   "Inhibitors of deacetylases suppress oncogenic KIT signaling,
RT   acetylate HSP90, and induce apoptosis in gastrointestinal stromal
RT   tumors.";
RL   Cancer Res. 69:6941-6950(2009).
//
RX   PubMed=25239608; DOI=10.1158/1078-0432.CCR-14-1397;
RA   Garner A.P., Gozgit J.M., Anjum R., Vodala S., Schrock A.B., Zhou T.-J.,
RA   Serrano C., Eilers G., Zhu M.-J., Ketzer J., Wardwell S., Ning Y.,
RA   Song Y., Kohlmann A., Wang F., Clackson T., Heinrich M.C.,
RA   Fletcher J.A., Bauer S., Rivera V.M.;
RT   "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and
RT   shows therapeutic potential in heavily pretreated gastrointestinal
RT   stromal tumor (GIST) patients.";
RL   Clin. Cancer Res. 20:5745-5755(2014).
//
RX   PubMed=29866822; DOI=10.1073/pnas.1802079115;
RA   Hemming M.L., Lawlor M.A., Zeid R., Lesluyes T., Fletcher J.A.,
RA   Raut C.P., Sicinska E.T., Chibon F., Armstrong S.A., Demetri G.D.,
RA   Bradner J.E.;
RT   "Gastrointestinal stromal tumor enhancers support a transcription
RT   factor network predictive of clinical outcome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E5746-E5755(2018).
//
RX   PubMed=30488756; DOI=10.1080/15384101.2018.1553335;
RA   Tu Y.-Q., Zuo R., Ni N., Eilers G., Wu D.-L., Pei Y.-T., Nie Z.-M.,
RA   Wu Y.-Q., Wu Y.-H., Ou W.-B.;
RT   "Activated tyrosine kinases in gastrointestinal stromal tumor with
RT   loss of KIT oncoprotein expression.";
RL   Cell Cycle 17:2577-2592(2018).
//